why choose us

First received: September 02, 2022

Clinical Trial: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed and Refractory Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Brief Summary: The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).

Read more